The DOI matches its Crossref record.
Liver Injury From Tumor Necrosis Factor-α Antagonists: Analysis of Thirty-four Cases
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Treatment decisions are often based on experience gained from case reports or expert opinion.
“Treatment decisions are often based on experience gained from case reports or expert opinion.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [35]
There is very limited data on the dose of corticosteroids used to treat DI-ALH in the published literature.
“There is very limited data on the dose of corticosteroids used to treat DI-ALH in the published literature.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 43
- Bezabeh, 2010, Clinically significant liver injury in patients treated with natalizumab, Aliment Pharmacol Ther, 31, 1028, 10.1111/j.1365-2036.2010.04262.x · DOI
- Carroll, 2008, Use of tumor necrosis factor-α inhibitors in patients with chronic hepatitis B infection, Semin Arthritis Rheum, 38, 208, 10.1016/j.semarthrit.2007.10.011 · DOI
- García Aparicio, 2007, Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab, Clin Rheumatol, 26, 811, 10.1007/s10067-006-0253-y · DOI
- Thiéfin, 2008, Infliximab-induced hepatitis: absence of cross-toxicity with etanercept, Joint Bone Spine, 75, 737, 10.1016/j.jbspin.2007.12.009 · DOI
- Fontana, 2010, Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop, Hepatology, 52, 730, 10.1002/hep.23696 · DOI
- Benichou, 1993, Causality assessment of adverse reactions to drugs: II—an original model for validation of drug causality assessment methods: case reports with positive rechallenge, J Clin Epidemiol, 46, 1331, 10.1016/0895-4356(93)90102-7 · DOI · Paper page
- Becker, 2008, Etanercept tolerance in a patient with previous infliximab-induced hepatitis, Clin Rheumatol, 27, 1597, 10.1007/s10067-008-1000-3 · DOI
- Féau, 2010, [Acute drug-induced hepatitis during adalimumab and ibuprofen treatment], Gastroenterol Clin Biol, 34, 420, 10.1016/j.gcb.2010.01.017 · DOI
- Iwamoto, 2011, Successful treatment with very low-dose etanercept in a patient with etanercept-induced liver dysfunction, Rheumatol Int, 31, 561, 10.1007/s00296-010-1456-8 · DOI
- Leak, 2008, Hepatotoxicity associated with etanercept in psoriatic arthritis, J Rheumatol, 35, 2286, 10.3899/jrheum.080521 · DOI
- Menghini, 2001, Infliximab-associated reversible cholestatic liver disease, Mayo Clin Proc, 76, 84, 10.4065/76.1.84 · DOI
- Tobon, 2007, Serious liver disease induced by infliximab, Clin Rheumatol, 26, 578, 10.1007/s10067-005-0169-y · DOI
- Massarotti, 2009, Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity, Int J Immunopathol Pharmacol, 22, 547, 10.1177/039463200902200234 · DOI
- Kluger, 2009, Efficiency and safety of etanercept after acute hepatitis induced by infliximab for psoriasis, Acta Derm Venereol, 89, 332, 10.2340/00015555-0619 · DOI
- Boetticher, 2008, A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis, Gastroenterology, 135, 1953, 10.1053/j.gastro.2008.08.057 · DOI
- Naveau, 2004, A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis, Hepatology, 39, 1390, 10.1002/hep.20206 · DOI
- Haennig, 2010, Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab, Gastroenterol Clin Biol, 34, e7, 10.1016/j.gcb.2010.01.016 · DOI
- Subramaniam, 2011, Infliximab-induced autoimmune hepatitis in Crohn's disease treated with budesonide and mycophenolate, Inflamm Bowel Dis, 17, E149, 10.1002/ibd.21880 · DOI
- Sokolove, 2010, Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis, Ann Rheum Dis, 69, 1612, 10.1136/ard.2009.112136 · DOI
- Viganò, 2012, Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management, Expert Opin Biol Ther, 12, 193, 10.1517/14712598.2012.646986 · DOI
- Wahie, 2006, Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis, Clin Exp Dermatol, 31, 460, 10.1111/j.1365-2230.2006.02086.x · DOI
- De Rycke, 2005, Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis, Arthritis Rheum, 52, 2192, 10.1002/art.21190 · DOI
- Gonnet-Gracia, 2008, Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers, Clin Exp Rheumatol, 26, 401
- Grasland, 2012, Autoimmune hepatitis induced by adalimumab with successful switch to abatacept, Eur J Clin Pharmacol, 68, 895, 10.1007/s00228-011-1191-4 · DOI
- Adar, 2010, Adalimumab-induced autoimmune hepatitis, J Clin Gastroenterol, 44, e20, 10.1097/MCG.0b013e3181a745e7 · DOI
- Fairhurst, 2009, Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisis, Clin Exp Dermatol, 34, 421, 10.1111/j.1365-2230.2008.03088.x · DOI
- Fathalla, 2008, Development of autoimmune hepatitis in a child with systemic-onset juvenile idiopathic arthritis during therapy with etanercept, J Clin Rheumatol, 14, 297, 10.1097/RHU.0b013e318188b1df · DOI
- Germano, 2005, Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis, Ann Rheum Dis, 64, 1519, 10.1136/ard.2004.032821 · DOI
- Harada, 2008, A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis, Clin Rheumatol, 27, 1063, 10.1007/s10067-008-0885-1 · DOI
- Ozorio, 2007, Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis, Med J Aust, 187, 524, 10.5694/j.1326-5377.2007.tb01396.x · DOI
- Saleem, 2001, Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles et al, Arthritis Rheum, 44, 1966, 10.1002/1529-0131(200108)44:8<1966::AID-ART339>3.0.CO;2-3 · DOI
- Björnsson, 2010, Drug-induced autoimmune hepatitis: clinical characteristics and prognosis, Hepatology, 51, 2040, 10.1002/hep.23588 · DOI · Paper page
- Mancini, 2010, Infliximab-related hepatitis: discussion of a case and review of the literature, Intern Emerg Med, 5, 193, 10.1007/s11739-009-0342-4 · DOI
- Carlsen, 2009, Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept, Clin Rheumatol, 28, 1001, 10.1007/s10067-009-1179-y · DOI
- Soto-Fernández, 2006, [Infliximab-induced hepatitis in a patient with Crohn's disease], Gastroenterol Hepatol, 29, 321, 10.1157/13087475 · DOI
- Poulin, 2010, Drug-induced hepatitis and lupus during infliximab treatment for psoriasis: case report and literature review, J Cutan Med Surg, 14, 100, 10.2310/7750.2009.09007 · DOI
- Marques, 2008, Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis, Inflamm Bowel Dis, 14, 723, 10.1002/ibd.20293 · DOI
- Ierardi, 2006, Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis, Clin Drug Invest, 26, 673, 10.2165/00044011-200626110-00008 · DOI
- Goujon, 2010, Autoimmune hepatitis in two psoriasis patients treated with inflixmab, J Am Acad Dermatol, 63, e43, 10.1016/j.jaad.2009.02.029 · DOI
- Doyle, 2011, Autoimmune hepatitis during infliximab therapy for Crohn's disease: a case report, J Crohns Colitis, 5, 253, 10.1016/j.crohns.2010.12.007 · DOI
- Moum, 2007, Occurrence of hepatoxicicty and elevated liver enzymes in a Crohn's disease patient treated with infliximab, Inflamm Bowel Dis, 13, 1584, 10.1002/ibd.20230 · DOI
- Cravo, 2010, Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab, BioDrugs, 24, 25, 10.2165/11586210-000000000-00000 · DOI
- Goldfeld, 2011, Infliximab-induced autoimmune hepatitis with successful switch to adalimumab in a patient with Crohn's disease: the index case, Dig Dis Sci, 56, 3386, 10.1007/s10620-011-1748-1 · DOI
Cited by
Sorted by citations
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Drug-induced liver injury—types and phenotypes
Hoofnagle, J. H., & Björnsson, E. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1816149 · Cited by 652
Hepatotoxicity of green tea: an update
Mazzanti, G., Di Sotto, A., & Vitalone, A. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1521-x · Cited by 189
Andrade, R. J., Aithal, G. P., de Boer, Y. S., Liberal, R., Gerbes, A., Regev, A., Terziroli Beretta-Piccoli, B., Schramm, C., Kleiner, D. E., De Martin, E., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.033 · Cited by 166
Self-citationBiologic and checkpoint inhibitor‐induced liver injury: a systematic literature review
Shah, P., Sundaram, V., & Björnsson, E. (2020) · Hepatology Communications · doi:10.1002/hep4.1465 · Cited by 64
The contemporary epidemiology, causes, and management of drug-induced liver injury
Swanson, L., & Fontana, R. J. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000001011
Self-citation
Metadata
- Authors
- Ghabril, M., Bonkovsky, H. L., Kum, C., Davern, T., Hayashi, P. H., Kleiner, D. E., Serrano, J., Rochon, J., Fontana, R. J., & Bonacini, M.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 11
- Issue
- 5
- Pages
- 558-564.e3
- ISSN
- 1542-3565
- PMC
- PMC3865702
- Cited by
- 196
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
